Kala Pharmaceuticals (NSDQ:KALA) announced shares ticked up before hours today on first-quarter results that were mixed compared to the consensus forecast.
The Watertown, Mass.-based company posted losses of -$30.4 million, or -49¢ per share, on sales of $3.2 million for the three months ended March 31, 2021, for a -38.5% bottom-line slide despite revenues that more than tripled year-over-year.
Get the full story at our sister site, Drug Delivery Business News.